Impact of CMV therapy with valganciclovir on immune activation and the HIV viral load in semen and blood: an observational clinical study
- PMID: 24091693
- DOI: 10.1097/01.qai.0000435256.34306.c1
Impact of CMV therapy with valganciclovir on immune activation and the HIV viral load in semen and blood: an observational clinical study
Abstract
Background: The HIV RNA viral load (VL) in vaginal secretions and semen is an independent predictor of HIV transmission. Blood VL is associated with semen VL, and local mucosal factors, such as semen cytomegalovirus (CMV) reactivation, may play an important role.
Methods: Twenty-one HIV-CMV-coinfected, antiretroviral-naive men received 900 mg of oral valganciclovir once daily for 2 weeks in an open-label study. Blood and semen were collected at baseline, after 2 weeks of valganciclovir, and 2 months after therapy completion. The primary end point was change in semen HIV levels at 2 weeks, and the secondary end points were change in semen HIV VL at 2 months and change in semen CMV levels.
Results: The HIV VLs fell significantly at 2 weeks in semen (median 3.44-3.02 log10 copies/mL, P = 0.02) and blood (median 3.61-3.10 log10 copies/mL, P < 0.01) and returned to baseline after therapy completion (median 3.24 and 3.71 log10 copies/mL in semen and blood, respectively). Semen CMV levels also fell on treatment (median 2.13-1.62 log10 copies/mL, P < 0.01) and continued to fall after therapy completion (median 0.91 log10 copies/mL at week 8, P < 0.001 vs. baseline). The reduced semen CMV VL was associated with decreased semen T-cell activation and enhanced CMV-specific T-cell responses in blood; changes in the semen HIV VL were not associated with immune parameters.
Conclusions: Although valganciclovir therapy was associated with reduced HIV and semen CMV levels, these results suggest that the reduced HIV VL was a direct drug effect rather than a CMV antiviral effect or CMV-associated immune alterations.
Similar articles
-
Similar reduction of cytomegalovirus DNA load by oral valganciclovir and intravenous ganciclovir on pre-emptive therapy after renal and renal-pancreas transplantation.Antivir Ther. 2005;10(1):119-23. Antivir Ther. 2005. PMID: 15751769 Clinical Trial.
-
Oral valganciclovir as pre-emptive therapy has similar efficacy on cytomegalovirus DNA load reduction as intravenous ganciclovir in allogeneic stem cell transplantation recipients.Bone Marrow Transplant. 2006 Apr;37(7):693-8. doi: 10.1038/sj.bmt.1705311. Bone Marrow Transplant. 2006. PMID: 16501590
-
Valganciclovir reduces T cell activation in HIV-infected individuals with incomplete CD4+ T cell recovery on antiretroviral therapy.J Infect Dis. 2011 May 15;203(10):1474-83. doi: 10.1093/infdis/jir060. J Infect Dis. 2011. PMID: 21502083 Free PMC article. Clinical Trial.
-
Oral valganciclovir versus ganciclovir as delayed pre-emptive therapy for patients after allogeneic hematopoietic stem cell transplant: a pilot trial (04-0274) and review of the literature.Transpl Infect Dis. 2012 Jun;14(3):259-67. doi: 10.1111/j.1399-3062.2011.00689.x. Epub 2011 Oct 28. Transpl Infect Dis. 2012. PMID: 22093134 Review.
-
Oral valganciclovir: a new option for treatment of cytomegalovirus infection and disease in immunocompromised hosts.Expert Opin Investig Drugs. 2001 Sep;10(9):1745-53. doi: 10.1517/13543784.10.9.1745. Expert Opin Investig Drugs. 2001. PMID: 11772283 Review.
Cited by
-
Molecular Pathogenesis of Human Immunodeficiency Virus-Associated Disease of Oropharyngeal Mucosal Epithelium.Biomedicines. 2023 May 14;11(5):1444. doi: 10.3390/biomedicines11051444. Biomedicines. 2023. PMID: 37239115 Free PMC article. Review.
-
Host Genetics of Cytomegalovirus Pathogenesis.Front Genet. 2019 Jul 23;10:616. doi: 10.3389/fgene.2019.00616. eCollection 2019. Front Genet. 2019. PMID: 31396258 Free PMC article. Review.
-
Elevated cytomegalovirus IgG antibody levels are associated with HIV-1 disease progression and immune activation.AIDS. 2017 Mar 27;31(6):807-813. doi: 10.1097/QAD.0000000000001412. AIDS. 2017. PMID: 28121712 Free PMC article.
-
Cytomegalovirus and paediatric HIV infection.J Virus Erad. 2016 Oct 5;2(4):208-214. doi: 10.1016/S2055-6640(20)30873-6. J Virus Erad. 2016. PMID: 27781102 Free PMC article.
-
Human Immunodeficiency Virus (HIV) and Human Cytomegalovirus (HCMV) Coinfection of Infant Tonsil Epithelium May Synergistically Promote both HIV-1 and HCMV Spread and Infection.J Virol. 2021 Aug 25;95(18):e0092121. doi: 10.1128/JVI.00921-21. Epub 2021 Aug 25. J Virol. 2021. PMID: 34232730 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical